NeuroPace Inc (NPCE) — SEC Financial Statements & Analysis

NeuroPace Inc (NPCE) is a surgical & medical instruments & apparatus company, incorporated in DE. NeuroPace Inc trades on Nasdaq as: NPCE. NeuroPace Inc (NPCE)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11. Based on that filing, NeuroPace Inc carries a market cap of $541.92M, a P/E ratio of -28.35x, a P/B ratio of 45.60x, a P/S ratio of 5.27x, an enterprise value of $588.15M, and an EV/EBITDA multiple of -43.68x. On profitability, it posts a gross margin of 78.38%, an operating margin of -13.33%, a net margin of -18.58%, a Return on Equity (ROE) of -122.05%, a Return on Assets (ROA) of -18.82%, and a Return on Invested Capital (ROIC) of -23.45%. Per share, it reports EPS of $-0.56, diluted EPS of $-0.56, free cash flow per share of $-0.34, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 21.65% year-over-year, net income growth of -26.32% year-over-year, and EPS growth of -29.00% year-over-year. On the balance sheet, it maintains a current ratio of 4.94x, a quick ratio of 3.82x, working capital of $68.76M, a debt-to-equity ratio of 7.16x, a debt ratio of 0.88, an interest coverage ratio of -2.17x, free cash flow of $-11.61M (TTM), and net debt of $46.23M. Figures sourced from SEC EDGAR.

Market Cap

$541.92M

P/E TTM

-28.35x

EPS TTM

$-0.56

P/B TTM

45.60x

ROE TTM

-122.05%

ROA TTM

-18.82%

Debt To Equity

7.16x

Free Cash Flow TTM

$-11.61M

Net Revenue TTM Growth 1Y

21.65%

Data as of 2026-06-30 · Source: SEC EDGAR